• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

过氧化物酶体增殖物激活受体γ配体的CHARMM力场参数化

CHARMM Force Field Parameterization of Peroxisome Proliferator-Activated Receptor γ Ligands.

作者信息

Mottin Melina, Souza Paulo C T, Ricci Clarisse G, Skaf Munir S

机构信息

Institute of Chemistry, University of Campinas-UNICAMP, P.O. Box 6154, Campinas 13082-864, SP, Brazil.

Faculty of Pharmacy, Federal University of Goias, Goiânia 74605-170, GO, Brazil.

出版信息

Int J Mol Sci. 2016 Dec 22;18(1):15. doi: 10.3390/ijms18010015.

DOI:10.3390/ijms18010015
PMID:28025495
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5297650/
Abstract

The peroxisome proliferator-activated receptor γ (PPARγ) ligands are important therapeutic drugs for the treatment of type 2 diabetes, obesity and cardiovascular diseases. In particular, partial agonists and non-agonists are interesting targets to reduce glucose levels, presenting few side effects in comparison to full agonists. In this work, we present a set of CHARMM-based parameters of a molecular mechanics force field for two PPARγ ligands, GQ16 and SR1664. GQ16 belongs to the thiazolidinedione class of drugs and it is a PPARγ partial agonist that has been shown to promote the "browning" of white adipose tissue. SR1664 is the precursor of the PPARγ non-agonist class of ligands that activates PPARγ in a non-classical manner. Here, we use quantum chemical calculations consistent with the CHARMM protocol to obtain bonded and non-bonded parameters, including partial atomic charges and effective torsion potentials for both molecules. The newly parameterized models were evaluated by examining the behavior of GQ16 and SR1664 free in water and bound to the ligand binding pocket of PPARγ using molecular dynamics simulations. The potential parameters derived here are readily transferable to a variety of pharmaceutical compounds and similar PPARγ ligands.

摘要

过氧化物酶体增殖物激活受体γ(PPARγ)配体是治疗2型糖尿病、肥胖症和心血管疾病的重要治疗药物。特别是,部分激动剂和非激动剂是降低血糖水平的有趣靶点,与完全激动剂相比副作用较少。在这项工作中,我们提出了基于CHARMM的分子力学力场的一组参数,用于两种PPARγ配体GQ16和SR1664。GQ16属于噻唑烷二酮类药物,是一种PPARγ部分激动剂,已被证明可促进白色脂肪组织的“褐变”。SR1664是PPARγ非激动剂类配体的前体,它以非经典方式激活PPARγ。在这里,我们使用与CHARMM协议一致的量子化学计算来获得键合和非键合参数,包括两个分子的部分原子电荷和有效扭转势。通过使用分子动力学模拟检查GQ16和SR1664在水中自由以及与PPARγ配体结合口袋结合时的行为,对新参数化的模型进行了评估。这里导出的势参数很容易转移到各种药物化合物和类似的PPARγ配体上。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0cb5/5297650/3a20e634b505/ijms-18-00015-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0cb5/5297650/868991e87f87/ijms-18-00015-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0cb5/5297650/a63869e26978/ijms-18-00015-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0cb5/5297650/6da0e0f6e50e/ijms-18-00015-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0cb5/5297650/e52467eb582f/ijms-18-00015-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0cb5/5297650/3b5acaf8931f/ijms-18-00015-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0cb5/5297650/3a20e634b505/ijms-18-00015-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0cb5/5297650/868991e87f87/ijms-18-00015-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0cb5/5297650/a63869e26978/ijms-18-00015-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0cb5/5297650/6da0e0f6e50e/ijms-18-00015-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0cb5/5297650/e52467eb582f/ijms-18-00015-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0cb5/5297650/3b5acaf8931f/ijms-18-00015-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0cb5/5297650/3a20e634b505/ijms-18-00015-g006.jpg

相似文献

1
CHARMM Force Field Parameterization of Peroxisome Proliferator-Activated Receptor γ Ligands.过氧化物酶体增殖物激活受体γ配体的CHARMM力场参数化
Int J Mol Sci. 2016 Dec 22;18(1):15. doi: 10.3390/ijms18010015.
2
A novel non-agonist peroxisome proliferator-activated receptor γ (PPARγ) ligand UHC1 blocks PPARγ phosphorylation by cyclin-dependent kinase 5 (CDK5) and improves insulin sensitivity.一种新型非激动剂过氧化物酶体增殖物激活受体γ(PPARγ)配体UHC1可阻断细胞周期蛋白依赖性激酶5(CDK5)介导的PPARγ磷酸化,并改善胰岛素敏感性。
J Biol Chem. 2014 Sep 19;289(38):26618-26629. doi: 10.1074/jbc.M114.566794. Epub 2014 Aug 6.
3
Unique Interactome Network Signatures for Peroxisome Proliferator-activated Receptor Gamma (PPARγ) Modulation by Functional Selective Ligands.功能性选择性配体对过氧化物酶体增殖物激活受体γ(PPARγ)调节的独特相互作用网络特征。
Mol Cell Proteomics. 2017 Dec;16(12):2098-2110. doi: 10.1074/mcp.RA117.000308. Epub 2017 Sep 29.
4
Ligands for the Nuclear Peroxisome Proliferator-Activated Receptor Gamma.核过氧化物酶体增殖物激活受体 γ 的配体。
Trends Pharmacol Sci. 2015 Oct;36(10):688-704. doi: 10.1016/j.tips.2015.06.010.
5
Study of the interactions between Edaglitazone and Ciglitazone with PPARγ and their antiplatelet profile.研究埃格列汀酮和西格列汀酮与 PPARγ 的相互作用及其抗血小板特性。
Life Sci. 2017 Oct 1;186:59-65. doi: 10.1016/j.lfs.2017.07.031. Epub 2017 Jul 28.
6
Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation.一种非激动剂 PPARγ 配体通过阻断 Cdk5 介导的磷酸化发挥抗糖尿病作用。
Nature. 2011 Sep 4;477(7365):477-81. doi: 10.1038/nature10383.
7
Multi-conformation dynamic pharmacophore modeling of the peroxisome proliferator-activated receptor γ for the discovery of novel agonists.多构象动态药效基团模型在过氧化物酶体增殖物激活受体γ上的建立及其在新型激动剂发现中的应用。
J Mol Graph Model. 2013 Nov;46:1-9. doi: 10.1016/j.jmgm.2013.08.012. Epub 2013 Aug 22.
8
Study of new interactions of glitazone's stereoisomers and the endogenous ligand 15d-PGJ2 on six different PPAR gamma proteins.研究新型手性格列酮立体异构体与内源性配体 15d-PGJ2 在六种不同的 PPARγ 蛋白上的新相互作用。
Biochem Pharmacol. 2017 Oct 15;142:168-193. doi: 10.1016/j.bcp.2017.07.012. Epub 2017 Jul 15.
9
Discovery of a novel selective PPARγ ligand with partial agonist binding properties by integrated in silico/in vitro work flow.通过整合的计算/体外工作流程发现具有部分激动剂结合特性的新型选择性 PPARγ 配体。
J Chem Inf Model. 2013 Apr 22;53(4):923-37. doi: 10.1021/ci3006148. Epub 2013 Mar 19.
10
Development of an In Vitro Screening Platform for the Identification of Partial PPARγ Agonists as a Source for Antidiabetic Lead Compounds.开发体外筛选平台鉴定部分过氧化物酶体增殖物激活受体γ激动剂作为抗糖尿病先导化合物的来源。
Molecules. 2018 Sep 22;23(10):2431. doi: 10.3390/molecules23102431.

本文引用的文献

1
GQ-16, a TZD-Derived Partial PPARγ Agonist, Induces the Expression of Thermogenesis-Related Genes in Brown Fat and Visceral White Fat and Decreases Visceral Adiposity in Obese and Hyperglycemic Mice.GQ-16,一种噻唑烷二酮类衍生的部分过氧化物酶体增殖物激活受体γ激动剂,可诱导棕色脂肪和内脏白色脂肪中与产热相关基因的表达,并减少肥胖和高血糖小鼠的内脏脂肪量。
PLoS One. 2016 May 3;11(5):e0154310. doi: 10.1371/journal.pone.0154310. eCollection 2016.
2
Review of the Structural and Dynamic Mechanisms of PPARγ Partial Agonism.过氧化物酶体增殖物激活受体γ(PPARγ)部分激动作用的结构与动力学机制综述
PPAR Res. 2015;2015:816856. doi: 10.1155/2015/816856. Epub 2015 Sep 8.
3
Structural and Dynamical Insight into PPARγ Antagonism: In Silico Study of the Ligand-Receptor Interactions of Non-Covalent Antagonists.
对过氧化物酶体增殖物激活受体γ(PPARγ)拮抗作用的结构与动力学洞察:非共价拮抗剂配体-受体相互作用的计算机模拟研究
Int J Mol Sci. 2015 Jul 8;16(7):15405-24. doi: 10.3390/ijms160715405.
4
Pharmacological repression of PPARγ promotes osteogenesis.PPARγ 的药理学抑制促进骨生成。
Nat Commun. 2015 Jun 12;6:7443. doi: 10.1038/ncomms8443.
5
Molecular Recognition of PPARγ by Kinase Cdk5/p25: Insights from a Combination of Protein-Protein Docking and Adaptive Biasing Force Simulations.激酶Cdk5/p25对PPARγ的分子识别:来自蛋白质-蛋白质对接和自适应偏置力模拟相结合的见解
J Phys Chem B. 2015 Jul 2;119(26):8330-9. doi: 10.1021/acs.jpcb.5b04269. Epub 2015 Jun 19.
6
Peroxisome Proliferator-Activated Receptor γ (PPARγ) and Ligand Choreography: Newcomers Take the Stage.过氧化物酶体增殖物激活受体 γ (PPARγ)及其配体的协同作用:新角色登场。
J Med Chem. 2015 Jul 23;58(14):5381-94. doi: 10.1021/jm501155f. Epub 2015 Apr 9.
7
An ERK/Cdk5 axis controls the diabetogenic actions of PPARγ.一条细胞外信号调节激酶/细胞周期蛋白依赖性激酶5轴调控过氧化物酶体增殖物激活受体γ的致糖尿病作用。
Nature. 2015 Jan 15;517(7534):391-5. doi: 10.1038/nature13887. Epub 2014 Nov 17.
8
Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes.噻唑烷二酮类药物与2型糖尿病胰岛素增敏作用的前景。
Cell Metab. 2014 Oct 7;20(4):573-91. doi: 10.1016/j.cmet.2014.08.005. Epub 2014 Sep 18.
9
A novel non-agonist peroxisome proliferator-activated receptor γ (PPARγ) ligand UHC1 blocks PPARγ phosphorylation by cyclin-dependent kinase 5 (CDK5) and improves insulin sensitivity.一种新型非激动剂过氧化物酶体增殖物激活受体γ(PPARγ)配体UHC1可阻断细胞周期蛋白依赖性激酶5(CDK5)介导的PPARγ磷酸化,并改善胰岛素敏感性。
J Biol Chem. 2014 Sep 19;289(38):26618-26629. doi: 10.1074/jbc.M114.566794. Epub 2014 Aug 6.
10
All-atom empirical potential for molecular modeling and dynamics studies of proteins.蛋白质分子建模和动力学研究的全原子经验势。
J Phys Chem B. 1998 Apr 30;102(18):3586-616. doi: 10.1021/jp973084f.